GSK To Shell Out $21.5M To Exit Wellbutrin Antitrust Suit
A Pennsylvania federal judge on Monday signed off on a $21.5 million settlement between GlaxoSmithKline PLC and employee benefit plans in a class action alleging the pharmaceuticals giant filed sham patent...To view the full article, register now.
Already a subscriber? Click here to view full article